Mixtard

RSS

insulin human (rDNA)

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal products for Human Use (CHMP) assessed the studies performed, to reach its recommendations on how to use the medicine.

If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 12/10/2020

Authorisation details

Product details
Name
Mixtard
Agency product number
EMEA/H/C/000428
Active substance
insulin human
International non-proprietary name (INN) or common name
insulin human (rDNA)
Therapeutic area (MeSH)
Diabetes Mellitus
Anatomical therapeutic chemical (ATC) code
A10AD01
Publication details
Marketing-authorisation holder
Novo Nordisk A/S
Revision
19
Date of issue of marketing authorisation valid throughout the European Union
07/10/2002
Contact address

Novo Allé
DK-2880 Bagsvaerd
Denmark

Product information

24/09/2020 Mixtard - EMEA/H/C/000428 - WS/1901

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Drugs used in diabetes

Therapeutic indication

Treatment of diabetes mellitus.

Assessment history

How useful was this page?

Add your rating
Average
3 ratings